EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

L-TPS09 - Allergen immunotherapy 7

Sunday 02 Jun, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
Allergenic identification and characterization of holm oak (Quercus ilex) pollen
Allergy in paediatrics: a current overview on paediatric allergists of Spain, Portugal and Italy
Development of monoclonal antibodies against dog allergens and their application for the analysis of dog allergen extracts
Emotional experience of respiratory allergy patient journey: focus on the first specialist consultation
Evaluation of the efficacy, adverse effects, and cost-effectiveness of sublingual immunotherapy with dominant allergens for allergic rhinitis due to respiratory allergens in adults and children
Improving Allergen-Immunotherapy: Practical Tools for Young Allergists
Meta-analysis of primary endpoint of PQ Grass field studies with optimized dose and treatment regimen of PQ Grass
Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system
Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted D.pteronyssinus-D.farinae allergen extract
Secondary endpoint profile is strongly supportive for the positive outcome of the pivotal Phase III study with PQ Grass
Short-term benefits of sublingual immunotherapy in routine clinical practice: deciphering factors influencing the patient satisfaction in the observational, prospective, longitudinal study PRACTIS
Spreading of sensitization to airborne allergens in patients under AIT
Stability of an allergoid with a mixture of Dermatophagoides pteronyssinus and dog dander